Immunoreactivity for p27 KIP1 and cyclin E is an independent predictor of survival in primary gastric non-hodgkin's lymphoma

Andrés J M Ferreri, Maurilio Ponzoni, Giancarlo Pruneri, Massimo Freschi, Roberta Rossi, Stefania Dell'Oro, Luca Baldini, Roberto Buffa, Nadia Carboni, Eugenio Villa, Giuseppe Viale

Research output: Contribution to journalArticle

Abstract

Our aim was to assess the prognostic implications of the expression of p27KIP1 and cyclin E in gastric lymphoma. We investigated the prognostic value of the immunoreactivity of these molecules in 92 cases of primary gastric lymphoma: 34 LGMLs, 24 DLCLMLs and 34 DLCLs. p27 was positive in 88% of LGMLs, 71% of DLCLMLs and 32% of DLCLs (p = 0.004); cyclin E was positive in 9%, 33% and 59% of cases, respectively (p <0.00001). p27/cyclin E immunoreactivity significantly correlated with histologic category, stage and LDH serum level. p27 immunoreactivity was significantly associated with better survival, whereas cyclin E reactivity was significantly related to worse outcome. Five-year CSS was 94% for patients with p27+/cyclin E- phenotype (n = 42), 79% for p27+/ cyclin E+ (n = 14) or p27-/cyclin E- (n = 16) phenotype and 60% for p27-/cyclin E+phenotype (n = 16) (p = 0.02). The prognostic role of p27/cyclin E expression was confirmed when analyzed separately within LGMLs and large-cell lymphomas. Immunoreactivity for p27 and cyclin E is an independent predictor of survival in PGLs that may be an adjunctive tool in identifying high-risk patients. It correlates with histologic category, stage and LDH serum level. p27-/cyclin E+ phenotype is associated with worse survival, probably due to a synergistic effect of both cell-cycle defects. The predictive role of these molecules within each histologic group of PGLs deserves to be confirmed in larger series.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalInternational Journal of Cancer
Volume94
Issue number4
DOIs
Publication statusPublished - Nov 15 2001

    Fingerprint

Keywords

  • Cell-cycle regulator
  • Cell-signaling pathway
  • Cyclin E
  • Diffuse large-cell lymphoma
  • Gastric lymphoma
  • MALT-type lymphoma
  • Non-Hodgkin's lymphoma
  • p27

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this